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EAbstract
Background: Several studies have indicated an association between tumor necrosis factor-alpha (TNF-α) or interleukin
(IL)-6 gene polymorphisms and lung cancer risk. However, the conclusions remain controversial.
Methods: An English literature screening about case-control trials with regard to TNF-α (-308G/A) or IL-6 (174G/C)
polymorphisms and lung cancer susceptibility was performed on PubMed, EMBASE, and EBSCO until November
2012. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated using STATA 11.0. Sensitivity
analysis was performed by sequential omission of individual studies. Publication bias was evaluated by Egger’s
linear regression test and funnel plots.
Results: Eight eligible studies, including 1,690 patients and 1,974 controls, were identified in this meta-analysis.
Compared with the control, no significant association was revealed between TNF-α-308G/A (GG + GC vs. CC:
OR = 1.10, 95% CI: 0.73 to 1.64; GG vs. GC + CC: OR = 1.02, 95% CI: 0.81 to 1.27; GC vs. CC: OR = 1.13, 95% CI: 0.73
to 1.77; GG vs. CC: OR = 1.04, 95% CI: 0.80 to 1.36; G vs. C: OR = 1.03, 95% CI: 0.90 to 1.18) or IL-6 174G/C (GG +
GC vs. CC: OR = 1.10, 95% CI: 0.73 to 1.64; GG vs. GC + CC: OR = 1.02, 95% CI: 0.81 to 1.27; GC vs. CC: OR = 1.13,
95% CI: 0.73 to 1.77; GG vs. CC: OR = 1.04, 95% CI: 0.80 to 1.36; G vs. C: OR = 1.03, 95% CI: 0.90 to 1.18) and lung
cancer risk. The pooled OR remained unchanged after removing the maximum-weight study and no publication bias
was observed.
Conclusions: The study raises the possibility of no correlation between the polymorphisms of the two genes and lung
cancer susceptibility. However, further researches with large-sample or subgroup analyses are necessary to validate the
conclusions.







Lung cancer is one of the most common causes of
cancer-related mortality worldwide, being responsible
for approximately 87,750 deaths in men and 72,590 in
women in 2012 [1]. Although air pollution and smoking
are believed to be important contributory factors for the
development of lung cancer [2], only one in ten persons
exposed to air pollution or tobacco ultimately develops
lung cancer, indicating that other factors, like genetic
factors, are also important as well [3].R
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flammation may exert important roles in the etiology of
lung cancer [4]. Cytokines from inflammatory cells can
increase intracellular reactive oxygen and nitrogen spe-
cies and cause DNA damage and epigenetic changes
(that is, promoter hyper-methylation), eventually silen-
cing tumor suppressors and promoting tumor initiation
[4]. Regulation of pro-inflammatory cytokine expressions
can inhibit tumor cell proliferation, angiogenesis, inva-
sion, and meta-stasis, but stimulate cells apoptosis [5,6].
Tumor necrosis factor-alpha (TNF-α) and interleukin
(IL)-6 are pleiotropic cytokines involved in inflammatory
response and cancer pathogenesis. Previous studies have
indicated that the high levels of both cytokines arehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients [7,8]. It is well known that genetic variants, es-
pecially the functional polymorphisms located in the
promoter region of candidate genes, may quantitatively
change the gene’s expression [9]. Therefore, several stud-
ies have been performed to investigate the associations
between the polymorphisms of the TNF-α (-308G/A) or
IL-6 (174G/C) and susceptibility to lung cancer. How-
ever, the conclusions remain controversial. Shih et al. dem-
onstrated that the patients carrying a homologous AA or
heterologous GA genotype at TNF-α-308 had a tendency
to develop into advanced disease [10]. Colakogullari et al.
reported that the IL-6 (174G/C) heterozygous genotype oc-
curred at a higher frequency in lung cancer patients while
the homozygous form (G/G) was more common in healthy
controls [11]. No associations were seen between TNF-α or
IL-6 polymorphisms and the risk of lung cancer by Seifart
et al. [12]. These inconsistent conclusions may result from
the small-sample size in each study and different inclusion
criteria as well as other factors. Therefore, it is essential to
carry out a meta-analysis to quantitatively integrate the re-
sults of previous reports and comprehensively evaluate their
association, which was not reported.DMethods
Literature screening
Eligible studies were identified by searching electronic
databases including PubMed (http://www.ncbi.nlm.nih.
gov/pubmed/), Excerpt Medica Database (EMBASE,
http://www.elsevier.com/online-tools/embase), and EBS-
COhost Online Research Databases (EBSCO, http://
www.ebscohost.com/) for relevant reports published be-
fore November 2012 using the following terms: (TNF
OR tumor necrosis factor OR IL-6 OR interleukin 6)
AND (Lung Cancer OR lung carcinoma OR lung tumor)
AND (polymorphism OR polymorphisms OR variant
OR variants). The computer search was supplemented
with manual searches for reference lists of all retrieved
review articles, primary studies, and abstracts from
meetings to retrieve additional studies.
Inclusion and exclusion criteria
The following criteria were used to enroll studies pub-
lished in English: (1) case-control trials with raw data
published before November 2012, without the limitation
of the research time, (2) the study investigates the asso-
ciations between TNF-α-308G/A or IL-6-174G/C and
lung cancer susceptibility, and (3) the size of the sam-
ples, distribution of alleles, genotype frequency, or other
information are available for both cases and controls.
Studies were excluded if one of the following existed:
(1) the design was based on family or sibling pairs, (2)






TEthe literatures were duplicate publications, and (4) there
was insufficient information for data extraction.
Data extraction
Two system evaluators independently searched and
screened the literatures. Data extraction was performed
in accordance with a pre-set form while inconsistencies
in the process were discussed or referred to a third
party. The following data were extracted: first author,
publication date, original research site, race, age of case,
number of case, number of control, type of control, the
polymerase chain reaction (PCR) method used for geno-
typing, and whether the gene distribution of the controls
was in compliance with the Hardy-Weinberg Equilib-
rium (HWE).
Statistical analysis
The pooled odds ratio (OR) and 95% confidence inter-
vals (CI) were calculated as the integrative indicators to
assess the associations between TNF-α-308G/A or IL-6-
174G/C and lung cancer susceptibility. Chi-square-test-
based Q statistic and I2 were used as the heterogeneity
indicators. If the result of the Q test was PQ < 0.05 or
I2 ≥ 50%, indicating the presence of heterogeneity, a
random-effects model was used to estimate the OR.
Otherwise, a fixed-effects model was used. For each
polymorphic locus, five comparison models, including
dominant model, recessive model, heterozygous geno-
type comparison, homozygous genotype comparison,
and allele comparison, were carried out. We checked the
genotype distribution of the controls if the papers did
not describe it.
To explore the heterogeneity across studies for the
dominant model of TNF-α-308G/A and lung cancer sus-
ceptibility, subgroup analyses according to region distri-
bution and detection method and meta-regression were
performed. Sensitivity analysis was performed by se-
quential omission of individual studies. Publication bias
was evaluated by Egger’s linear regression test [13]. Fi-
nally, publication bias was explored by Egger’s linear re-
gression test and funnel plots.
All statistical analyses were conducted by STATA 11.0
(Stata Corporation, College Station, TX, USA). All the P
values were determined from two-sided test and the sig-
nificant level was set at 0.05.
Results
Literature search and screening results
A total of 196 literatures were retrieved and screened
through reading title and abstract to remove duplicate,
non-case-control and non-target studies. Review of the
full text of the 13 articles further excluded five articles:
three did not study TNF-α-308G/A or IL-6-174G/C and





Figure 1 Flow chart for literature screening.





LEtotal of eight relevant studies [10-12,14-18] were in-
cluded in this meta-analysis, among which six studies
were [10-12,14-16] about TNF-α-308G/A and four stud-
ies about IL-6-174G/C [11,12,17,18] (Figure 1).
Basic information of the included studies
Tables 1 and 2 show the main features of the included
studies and genotype distribution, respectively. Seven
out of the eight studies were carried out in Europe while
only one in Asia. These studies were published during




TTable 1 Basic information for studies included
First author Year Country Ethnicity Polymorphisms
Helmig 2010 Germany European TNF-α 308G/A
Flego 2009 Croatia European TNF-α 308G/A
Stankovic 2009 Serbia European TNF-α 308G/A
Colakogullari 2008 Turkey European TNF-α 308G/A IL-6 174G/C
Vogel 2008 Denmark European IL-6 174G/C
Seifart 2006 Germany European TNF-α 308G/A IL-6 174G/C
Shih 2006 China Asian TNF-α 308G/A
Campa 2004 Norway European IL-6 174G/C
TNF: tumor necrosis factor; IL: interleukin; PCR: polymerase chain reaction; PCR-RFLP: p
polymerase chain reaction-sequence specific primer; HWE: Hardy-Weinberg Equilibrium
R
ETpeople, matching with the cases in age, sex, place of
residence, occupation, and other factors. There was no
study with genotype distribution departing from HWE.
Combination of quantitative data
TNF-α-308G/A and lung cancer susceptibility
Six case-control studies investigated the association be-
tween the TNF-α-308G/A and lung cancer susceptibility,
including 957 cases and 1,015 controls. The meta-
analysis suggests that the TNF-α-308G/A polymorph-
ism is not significantly associated with lung cancer riskNumber of cases Number of controls Method HWE
374 177 Real-time PCR Yes
230 230 PCR-RFLP Yes
70 102 PCR-RFLP Yes
44 59 PCR-SSP Yes
403 744 PCR Yes
117 243 PCR-RFLP Yes
202 205 PCR-RFLP Yes
250 214 Taqman Yes
olymerase chain reaction-restriction fragment length polymorphism; PCR-SSP:
.
Table 2 Distribution of genotype and allele for TNF-α-308G/A and IL-6-174G/C
Locus Research Number of case Number of control Number of case Number of control
GG GA AA GG GA AA G A G A
TNF-α 308G/A Helmig et al. 290 79 5 136 38 3 659 89 310 44
Flego et al. 169 52 9 171 53 6 390 70 395 65
Stankovic et al. 57 13 0 71 28 3 127 13 170 34
Colakogullari et al. 38 5 0 37 16 6 81 5 90 28
Seifart et al. 29 11 0 171 67 4 69 11 409 75
Shih et al. 110 75 15 169 34 2 295 105 372 38
GG GC CC GG GC CC G C G C
IL-6 174G/C Colakogullari et al. 10 29 5 27 22 9 49 39 76 40
Vogel et al. 105 202 96 204 361 179 412 394 769 719
Seifart et al. 19 16 4 90 107 46 54 24 287 199
Campa et al. 64 111 68 55 105 47 239 247 215 199
TNF: tumor necrosis factor; IL: interleukin.




LEin all the five comparison models with high heterogen-
eity (I2 > 50%) except GA vs. AA (dominant model,
GG + GA vs. AA: OR = 0.95, 95% CI: 0.30 to 2.99, P =
0.935; recessive model, GG vs. GA + AA: OR = 1.07,
95% CI: 0.55 to 2.10, P = 0.834; heterozygous genotype
comparison, GA vs. AA: OR = 0.81, 95% CI: 0.43 to
1.54, P = 0.524; homozygous genotype comparison, GG
vs. AA: OR = 1.00, 95% CI: 0.27 to 3.62, P = 0.994; allele
comparison, G vs. A: OR = 1.12, 95% CI: 0.58 to 2.14,
P = 0.734) (Table 3). Forest plot for the dominant
model of TNF-α-308G/A is shown in Figure 2.
In order to explore the source of heterogeneity, meta-
regression was performed for the dominant model of
TNF-α-308G/A. As shown in Table 4, detection
method (P = 0.485) and region (P = 0.121) were both
not the factors influencing the pooled effect for the
meta-analysis. Moreover, the subgroup analyses
(Table 5) demonstrated that mutant gene G acted as aA
C
TETable 3 Results for different comparison models
Locus Comparison OR (95% CI) Z
TNF-α 308G/A GG + GA vs. AA 0.95 (0.30 to 2.99) 0.08
GG vs. GA + AA 1.07 (0.55 to 2.10) 0.21
GA vs. AA 0.81 (0.43 to 1.54) 0.64
GG vs. AA 1.00 (0.27 to 3.62) 0.01
G vs. A 1.12 (0.58 to 2.14) 0.34
IL-6 174G/C GG + GC vs. CC 1.10 (0.73 to 1.64) 0.44
GG vs. GC + CC 1.02 (0.81 to 1.27) 0.15
GC vs. CC 1.13 (0.73 to 1.77) 0.55
GG vs. CC 1.04 (0.80 to 1.36) 0.29
G vs. C 1.03 (0.90 to 1.18) 0.49




Rdominant gene (OR = 0.12, 95% CI: 0.03 to 0.54; P =
0.006).
IL-6-174G/C and lung cancer susceptibility
Four case-control studies investigated the association be-
tween the IL-6-174G/C and lung cancer susceptibility,
containing 719 cases and 1,252 controls. All the studies
were carried out in Europe. Results for the five compari-
son models are listed in Table 3. Similarly, no significant
differences were observed in all comparison models with
high heterogeneity (I2 > 50%) across studies researching
GG +GC vs. CC and GC vs. CC (dominant model, GG
+GC vs. CC: OR = 1.10, 95% CI: 0.73 to 1.64, P = 0.658;
recessive model, GG vs. GC + CC: OR = 1.02, 95% CI:
0.81 to 1.27, P = 0.879; heterozygous genotype compari-
son, GC vs. CC: OR = 1.13, 95% CI: 0.73 to 1.77, P =
0.581; homozygous genotype comparison, GG vs. CC:
OR = 1.04, 95% CI: 0.80 to 1.36, P = 0.771; allele
A
RPA I
2 PQ Model Egger’s test
t value P value
0.935 55.6 0.046 R 1.38 0.240
0.834 88.0 0.000 R 1.39 0.238
0.524 0.0 0.503 F 1.85 0.138
0.994 65.0 0.014 R 1.28 0.2708
0.734 89.6 0.000 R 1.58 0.190
0.658 61.4 0.051 R 0.36 0.752
0.879 17.4 0.304 F −0.98 0.432
0.581 64.4 0.038 R 0.53 0.647
0.771 9.4 0.346 F −0.46 0.693
0.623 44.3 0.145 F −0.08 0.943
alue for between-study heterogeneity; F: a fixed-effects model; R: a
Figure 2 Forest plots of TNF-α gene polymorphisms and lung cancer risk in overall populations (contrast GG + GA vs. AA). OR: odds
ratio; TNF-α: tumor necrosis factor-alpha.





LEcomparison, G vs. C: OR = 1.03, 95% CI: 0.90 to 1.18, P
= 0.623). Forest plot for the dominant model of IL-6-
174G/C is shown in Figure 3.
Publication bias
According to Egger’s linear regression test, no publica-
tion bias existed in all of the comparisons for both loci
(Table 3). Moreover, the shape of funnel plots also sug-
gest no publication bias among the studies focusing on
TNF-α or IL-6 gene polymorphisms and lung cancer risk
(Figure 4).
Sensitivity analysis
Sensitivity analysis was done for each result, and the
pooled OR remained unchanged after removing the
maximum-weight study, indicating high reliability in our
conclusions (data not shown).
Discussion
Although the relationship between TNF-α (-308G/A) or
IL-6 (174G/C) polymorphisms and cancer susceptibility
[19-21] has been investigated previously, no studies were
performed to specifically explore their association with





TETable 4 Meta-regression for TNF-α polymorphisms and suscep
Coefficient Standard Error
Region 2.652 1.235
Detection method −0.741 0.933
Constant −3.278 2.817The present meta-analysis included eight studies, involv-
ing 1,676 cases and 2,267 controls. The results indicated
no significant lung cancer susceptibility with TNF-α-
308G/A or IL-6-174G/C polymorphism in the overall
study populations. Our findings are in accordance with
most of the related studies summarized in this meta-
analysis. Sensitivity and publication bias analyses en-
sured the reliability of the conclusions.
Theoretically, genetic polymorphisms in the promoter
region of the TNF-α and IL-6 genes could modulate
their protein expression. For example, the G to A transi-
tion in the promoter region at position -308 results in
higher expression levels of TNF-α [10,22]. Homozygotes
for the G allele have higher plasma IL-6 levels than car-
riers homozygous for the C allele [11,23]. However, the
current evidence provides a negative outcome, which
may be explained by the fact that a single polymorph-
ism/gene might have a limited impact on lung cancer
susceptibility. Our results do not exclude the possibility
that other polymorphisms or haplotypes in the TNF-α
and IL-6 gene could be related to lung carcinogenesis.
For example, Liang et al. demonstrated that G-to-A al-
teration at the -238G locus of the TNF-α gene and C-to-
G alteration at the -572C locus of the IL-6 genetibility to lung cancer (GG + GA vs. AA)
t P 95% CI
2.15 0.121 −1.278 to 6.582
−0.79 0.485 −3.710 to 2.229
−1.16 0.329 −12.244 to 5.687
Table 5 TNF-α polymorphisms (GG + GA vs. AA) and susceptibility to lung cancer by subgroup analyses of region and
detection method
N I2 P value for heterogeneity OR (95% CI) Z P
Region Europe 5 12.2 0.336 1.40 (0.70 to 2.78) 0.95 0.342
Asia 1 0.12 (0.03 to 0.54) 2.77 0.006
Detection method Real-time PCR 1 1.27 (0.30 to 5.39) 0.33 0.743
PCR-RFLP 4 54.5 0.086 0.60 (0.15 to 2.38) 0.73 0.465
PCR-SSP 1 10.57 (0.58 to 192.90) 1.59 0.112
PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR-SSP: polymerase chain reaction-sequence
specific primer; N: number of enrolled studies; OR: odds ratio; 95% CI: 95% confidence interval.
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D
LEcorrelated with the development of lung cancers [24].
Chen et al. showed that a two-single-nucleotide poly-
morphism (SNP) CC (-6331C and -572C) IL-6 promoter
haplotype was significantly more common among cases
than among controls in both groups, indicating this
haplotype is associated with increased lung cancer risk
[25]. Therefore, comprehensive haplotype-based or mul-
tiple SNP-based strategies may provide more precise in-
formation on the genetic contribution of TNF-α or IL-6
to cancer etiology in the future [21].
In addition, there were some limitations in this meta-
analysis that we need to pay attention to. First, our re-
sults were based on unadjusted estimates and a relatively
limited study number made it impossible to perform
subgroup analysis stratified by ethnicity, smoking status,
and different types of lung cancer. Some investigators
pointed out that cancer risk was significantly increased
for individuals with the CC genotype of IL-6 in African
populations, but not in Caucasian populations [20]. TheTEFigure 3 Forest plots of IL-6 gene polymorphisms and lung cancer ris






lack of the population of Africa may lead to the decrease
of studies and cause a deviation to final result. As we
know, lung cancer is broadly classified into two subtypes
basing on the microscopic appearance of the tumor cells:
small-cell lung cancer and non-small-cell lung cancer.
Moreover, according to pathological pattern, lung cancer
is classified into several subtypes, including squamous
cell carcinoma, adenocarcinoma, and bronchioloalveolar
carcinoma. They do not share the same pathogenesis,
which may complicate the results. Maybe that is why
Shih et al. [10] reached an opposite conclusion from
Seifart et al. [12]. Second, lack of individual data of each
study limited our precise estimation of the interactions
between SNP-SNP or SNP-environment factors.
Conclusions
In summary, the present meta-analysis demonstrates no
significant association between TNF-α-308G/A or IL-6-
174G/C and susceptibility to lung cancer. However,
A
RT
ICk in overall populations (contrast GG + GC vs. CC). IL-6: interleukin
Figure 4 Funnel plots of the odds ratios of lung cancer for TNF-α and IL-6 polymorphisms by number of individual studies. (A) TNF-α
gene polymorphism; (B) IL-6 gene polymorphism. IL-6: interleukin 6; OR, odds ratio; TNF-α: tumor necrosis factor-alpha.











LEfurther study is needed to evaluate the effects of
TNF-α or IL-6 polymorphisms on lung cancer sus-
ceptibility by using large-sample case-control studies
and involving different ethnicity, smoking status, or
pathological-type descriptions.Competing interest
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